北美患者来源异种移植 (PDX) 模型市场 – 行业趋势和 2030 年预测

北美患者来源异种移植 (PDX) 模型市场分析和规模

据美国癌​​症协会统计，2018年美国新增癌症病例1,735,350例。此外，美国国家癌症研究所正在扩大2018年癌症研究模型库，以纳入更多研究模型。在北美和美国，大规模PDX库正在建设中。美国国家癌症研究所宣布计划将其抗癌药物筛选系统从“NCI-60人类肿瘤细胞系”过渡到新系统。与细胞系衍生的异种移植模型相比，PDX模型有望在保留肿瘤异质性的同时，具有更好的治疗效果可预测性。

Data Bridge Market Research 分析，患者来源的异种移植 (PDX) 模型市场在 2022 年为 75167.97 万美元，预计到 2030 年将达到 269411.99 万美元，在 2023 年至 2030 年的预测期内复合年增长率为 17.3%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

北美患者来源异种移植 (PDX) 模型市场范围和细分  

Market Definition

PDX models are considered an effective tool in biomedical research and preclinical trials because both species have similarities and these models are capable of carrying the tumour's characteristics and studying the tumour and its heterogeneity. They aid in assessing tumour growth rate, life cycle, and growth rate under various conditions. They also aid in distinguishing between adult and paediatric cancer. The use of PDX models in basic cancer research and rug development enables the adoption of new therapies, patient-specific therapies, and personalized medicine.

North America Patient Derived Xenograft (PDX) Models Market Dynamics

Drivers

• Rising demand for PDX models for pharmacology and biomarker studies

Tumor xenograft and syngeneic models were traditionally used for oncology pharmacology, biomarker, and pharmacokinetics/pharmacodynamics research. The value of PDX models in normal research operations has increased as the availability and cost of PDX models supplied by both academic institutions and contract research businesses have increased. A cursory review of cancer discovery programmes published in the last three years reveals the use of PDX models at various stages of preclinical discovery and translational research. However, the PDX Model industry is increasingly incorporating PDX model readout as a critical component of the required data package for both internal usage and regulatory submission. The use of PDX models in drug development can be traced the use of PDX models in drug development back several decades.

• Growing prevalence of chronic diseases rising the demand for personalized medicines

The development of medicines for chronic diseases such as cancer has received a lot of attention. Cancer is now a major burden on healthcare systems worldwide. According to Worldwide cancer data released in 2020, approximately 18 million cancer cases and 10 million cancer deaths were recorded in 2020. In vitro and in vivo techniques are being developed to address the rising incidence of cancer and provide effective therapies to patients. Cancer is one of the leading causes of death worldwide. The disease has spread rapidly and is expected to spread significantly during the forecast period.

Each year, approximately 400 000 children are diagnosed with cancer. The most common cancers differ by country. As a result of the rising global prevalence of cancer, the market is being driven by an increase in the rate of diagnosis and demand for personalized medication.

Opportunities

• Growing adoption of humanized PDX models

Despite the fact that xenografts develop well in immunodeficient models, these models are primarily used to create PDX models. These models are insufficient for investigating stroma-tumour interactions, which are primarily responsible for tumour development and progression in patients. Humanized PDX models help with these challenges and are gaining popularity in the industry. To generate humanized xenograft models, immunodeficient mice (such as NOD SCID mice) are being reconstructed with bone marrow or peripheral blood cells and patient tumour implants. These models are ideal for studying the role of xenogeneic immune cells in overall anti-tumor immunity. They also help with the development of immunotherapy medications that target the immune system's effector arm.

Restraints/Challenges

• Unaffordable personalized PDX models

To develop individualized PDX models, a specimen of the patient's tumour is implanted and grown in a variety of immunocompromised models. It is then extracted, fragmented, and re-implanted in a larger group of models that have been treated with various medications and pharmacological combinations. Given the costs of developing and maintaining these models and the use of expensive medications in these models, PDX trials can cost thousands of dollars, even for a single patient. Using PDX models in government-funded fundamental research, on the other hand, could be prohibitively expensive. These are the primary factors limiting the adoption of PDX models.

This patient derived xenograft (PDX) models market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the patient derived xenograft (PDX) models market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the North America Patient Derived Xenograft (PDX) Models Market

Covid-19 had a negative impact on the North America patient-derived xenograft (PDX) models market due to the decline in productivity in life science organizations during the pandemic. Reduced pharma R&D deals in therapeutic areas, disruption of clinical trials, and country-specific lockdowns all had an effect on the market. Oncology, ID/anti-infectives, cardiovascular disease, and respiratory disease trials were the most impacted. The market will resume growth as the impact of COVID-19 is expected to weaken in the post-pandemic scenario.

Recent Developments

• In December 2020, Collagen Matrix, Inc., a global leader in collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners ("Linden") announced the acquisition of Sunstar's Degradable Solutions division. It included the GUIDOR branded line of resorbable synthetic medical implants. The acquisition aims to broaden the range of technologies available to customers.
• In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres, and the company signed agreements with Dana-Farber Cancer Institute and the University of Washington. This aids the company's product expansion and provides assistance to the oncology drug development community.

North America Patient Derived Xenograft (PDX) Models Market Scope

The patient derived xenograft (PDX) models market is segmented on the basis of type, tumour type, application, technique and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Mice Models
• Rat Models

Tumor Type

• Gastrointestinal Tumor Models
• Lung Tumor Models
• Haematological Tumor Models
• Gynecological Tumor Models
• Respiratory Tumor Models
• Urological Tumor Models
• Others

Application

• Preclinical Drug Development
• Precision Medicine
• Co-Clinical Trials
• Basic Cancer Research
• Biomarker Analysis
• Oncology Research

Technique

• Heterotopic Implantation
• Orthotropic Implantation

End User

• Academic and Research Organizations
• Contract Research Organizations
• Pharmaceutical and Biotechnological Companies
• Others

Patient Derived Xenograft (PDX) Models Market Regional Analysis/Insights

The patient derived xenograft (PDX) models market is analyzed and market size insights and trends are provided by country, type, tumour type, application, technique and end user as referenced above.

The countries covered in the patient derived xenograft (PDX) models market report are U.S., Canada and Mexico in North America.

U.S. is dominating the market due to the strategic initiatives by government and private sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The patient derived xenograft (PDX) models market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for patient derived xenograft (PDX) models market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the patient derived xenograft (PDX) models market. The data is available for historic period 2011-2021.

Competitive Landscape and Patient Derived Xenograft (PDX) Models Market Share Analysis

The patient derived xenograft (PDX) models market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to patient derived xenograft (PDX) models market.

Some of the major players operating in the patient derived xenograft (PDX) models market are:

• Crown Bioscience Inc. (U.S.)
• THE JACKSON LABORATORY (U.S.)
• Champions Oncology, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Wuxi AppTec (China)
• Oncodesign (Canada)
• Aragen Bioscience (India)
• Biocytogen (U.S.)
• Bioduro (U.S.)
• Creative Animodel (U.S.)
• Covance Inc. (U.S.)
• EPO Berlin-Buch GmbH (Germany)
• EUROPDX. (Belgium)
• Explora BioLabs (U.S.)
• Hera BioLabs (U.S.)
• Horizon discovery Ltd. (U.K.)
• Pharmatest Services (Finland)
• Urospehere SAS (Cyprus)
• Xentech (France)
• Xenopat (France)

Research Methodology: North America Patient Derived Xenograft (PDX) Models Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（Factbook）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

SKU-23306